These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
168 related articles for article (PubMed ID: 34899115)
1. Camouflaged Hybrid Cancer Cell-Platelet Fusion Membrane Nanovesicles Deliver Therapeutic MicroRNAs to Presensitize Triple-Negative Breast Cancer to Doxorubicin. Liu Y; Sukumar UK; Kanada M; Krishnan A; Massoud TF; Paulmurugan R Adv Funct Mater; 2021 Oct; 31(41):. PubMed ID: 34899115 [TBL] [Abstract][Full Text] [Related]
2. Leukocyte/platelet hybrid membrane-camouflaged dendritic large pore mesoporous silica nanoparticles co-loaded with photo/chemotherapeutic agents for triple negative breast cancer combination treatment. Zhang T; Liu H; Li L; Guo Z; Song J; Yang X; Wan G; Li R; Wang Y Bioact Mater; 2021 Nov; 6(11):3865-3878. PubMed ID: 33937590 [TBL] [Abstract][Full Text] [Related]
3. Erythrocyte-Cancer Hybrid Membrane Camouflaged Hollow Copper Sulfide Nanoparticles for Prolonged Circulation Life and Homotypic-Targeting Photothermal/Chemotherapy of Melanoma. Wang D; Dong H; Li M; Cao Y; Yang F; Zhang K; Dai W; Wang C; Zhang X ACS Nano; 2018 Jun; 12(6):5241-5252. PubMed ID: 29800517 [TBL] [Abstract][Full Text] [Related]
4. Sequentially-targeted biomimetic nano drug system for triple-negative breast cancer ablation and lung metastasis inhibition. Fan J; Liu B; Long Y; Wang Z; Tong C; Wang W; You P; Liu X Acta Biomater; 2020 Sep; 113():554-569. PubMed ID: 32569637 [TBL] [Abstract][Full Text] [Related]
5. Systemic Delivery of Anti-miRNA for Suppression of Triple Negative Breast Cancer Utilizing RNA Nanotechnology. Shu D; Li H; Shu Y; Xiong G; Carson WE; Haque F; Xu R; Guo P ACS Nano; 2015 Oct; 9(10):9731-40. PubMed ID: 26387848 [TBL] [Abstract][Full Text] [Related]
6. A Microfluidics-Based Scalable Approach to Generate Extracellular Vesicles with Enhanced Therapeutic MicroRNA Loading for Intranasal Delivery to Mouse Glioblastomas. Wang K; Kumar US; Sadeghipour N; Massoud TF; Paulmurugan R ACS Nano; 2021 Nov; 15(11):18327-18346. PubMed ID: 34723509 [TBL] [Abstract][Full Text] [Related]
7. Functional exosome-mediated co-delivery of doxorubicin and hydrophobically modified microRNA 159 for triple-negative breast cancer therapy. Gong C; Tian J; Wang Z; Gao Y; Wu X; Ding X; Qiang L; Li G; Han Z; Yuan Y; Gao S J Nanobiotechnology; 2019 Sep; 17(1):93. PubMed ID: 31481080 [TBL] [Abstract][Full Text] [Related]
8. Biomimetic nanovesicles made from iPS cell-derived mesenchymal stem cells for targeted therapy of triple-negative breast cancer. Zhao Q; Hai B; Zhang X; Xu J; Koehler B; Liu F Nanomedicine; 2020 Feb; 24():102146. PubMed ID: 31884039 [TBL] [Abstract][Full Text] [Related]
9. MicroRNA profiling implies new markers of chemoresistance of triple-negative breast cancer. Ouyang M; Li Y; Ye S; Ma J; Lu L; Lv W; Chang G; Li X; Li Q; Wang S; Wang W PLoS One; 2014; 9(5):e96228. PubMed ID: 24788655 [TBL] [Abstract][Full Text] [Related]
10. Macrophage-Derived Extracellular Vesicles as Drug Delivery Systems for Triple Negative Breast Cancer (TNBC) Therapy. Haney MJ; Zhao Y; Jin YS; Li SM; Bago JR; Klyachko NL; Kabanov AV; Batrakova EV J Neuroimmune Pharmacol; 2020 Sep; 15(3):487-500. PubMed ID: 31722094 [TBL] [Abstract][Full Text] [Related]
11. The miRNA-449 family mediates doxorubicin resistance in triple-negative breast cancer by regulating cell cycle factors. Tormo E; Ballester S; Adam-Artigues A; Burgués O; Alonso E; Bermejo B; Menéndez S; Zazo S; Madoz-Gúrpide J; Rovira A; Albanell J; Rojo F; Lluch A; Eroles P Sci Rep; 2019 Mar; 9(1):5316. PubMed ID: 30926829 [TBL] [Abstract][Full Text] [Related]
12. Hyaluronic acid-chitosan nanoparticles for co-delivery of MiR-34a and doxorubicin in therapy against triple negative breast cancer. Deng X; Cao M; Zhang J; Hu K; Yin Z; Zhou Z; Xiao X; Yang Y; Sheng W; Wu Y; Zeng Y Biomaterials; 2014 May; 35(14):4333-44. PubMed ID: 24565525 [TBL] [Abstract][Full Text] [Related]
13. Preparation, characterization, and in vitro tumor-suppressive effect of anti-miR-21-equipped RNA nanoparticles. Zhang T; Wu Y; Yang D; Wu C; Li H Biochem Biophys Res Commun; 2021 Jun; 558():107-113. PubMed ID: 33906109 [TBL] [Abstract][Full Text] [Related]
14. Platelet-Tumor Cell Hybrid Membrane-Camouflaged Nanoparticles for Enhancing Therapy Efficacy in Glioma. Wu L; Li Q; Deng J; Shen J; Xu W; Yang W; Chen B; Du Y; Zhang W; Ge F; Lei S; Li K; Wang Z Int J Nanomedicine; 2021; 16():8433-8446. PubMed ID: 35002237 [TBL] [Abstract][Full Text] [Related]
15. Effective Triple-Negative Breast Cancer Targeted Treatment Using iRGD-Modified RBC Membrane-Camouflaged Nanoparticles. Huang J; Lai W; Wang Q; Tang Q; Hu C; Zhou M; Wang F; Xie D; Zhang Q; Liu W; Zhang Z; Zhang R Int J Nanomedicine; 2021; 16():7497-7515. PubMed ID: 34803378 [TBL] [Abstract][Full Text] [Related]
16. Hyaluronic acid-coated PEI-PLGA nanoparticles mediated co-delivery of doxorubicin and miR-542-3p for triple negative breast cancer therapy. Wang S; Zhang J; Wang Y; Chen M Nanomedicine; 2016 Feb; 12(2):411-20. PubMed ID: 26711968 [TBL] [Abstract][Full Text] [Related]
17. Delivery of Anti-miRNA for Triple-Negative Breast Cancer Therapy Using RNA Nanoparticles Targeting Stem Cell Marker CD133. Yin H; Xiong G; Guo S; Xu C; Xu R; Guo P; Shu D Mol Ther; 2019 Jul; 27(7):1252-1261. PubMed ID: 31085078 [TBL] [Abstract][Full Text] [Related]
18. Intercellular adhesion molecule 1 antibody-mediated mesoporous drug delivery system for targeted treatment of triple-negative breast cancer. Wang M; Liu W; Zhang Y; Dang M; Zhang Y; Tao J; Chen K; Peng X; Teng Z J Colloid Interface Sci; 2019 Mar; 538():630-637. PubMed ID: 30554096 [TBL] [Abstract][Full Text] [Related]
19. Hybrid cell membrane-coated nanoparticles: A multifunctional biomimetic platform for cancer diagnosis and therapy. Chen HY; Deng J; Wang Y; Wu CQ; Li X; Dai HW Acta Biomater; 2020 Aug; 112():1-13. PubMed ID: 32470527 [TBL] [Abstract][Full Text] [Related]
20. Delivery of miR-381-3p Mimic by Mesenchymal Stem Cell-Derived Exosomes Inhibits Triple Negative Breast Cancer Aggressiveness; an In Vitro Study. Shojaei S; Hashemi SM; Ghanbarian H; Sharifi K; Salehi M; Mohammadi-Yeganeh S Stem Cell Rev Rep; 2021 Jun; 17(3):1027-1038. PubMed ID: 33410095 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]